Literature DB >> 827836

Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol.

J M Dickinson, D A Mitchison.   

Abstract

Serial viable counts on Mycobacterium tuberculosis exposed in vitro to isoniazid, rifampicin and ethambutol in Tween-albumin liquid medium showed no bactericidal synergism between isoniazid and rifampicin and no influence of ethambutol on the bactericidal activity of isoniazid or isoniazid plus rifampicin. Guinea-pigs with moderately advanced experimental tuberculosis were treated fro 11 weeks with either (1) ethambutol, (2) isoniazid, (3) isoniazid plus ethambutol, (4) isoniazid plus rifampicin, (5) isonaiazid plus rifampic in plus ethambutol, or (6) no chemotherapy. The amount of tuberculous disease was scored and the spleen cultured in groups killed at intervals from 0--7 1/2 months after the end of chemotherapy. The regimens containing rifampicin were no more bactericidal during treatment than the corresponding regimens without rifampicin, but the onset of relapse after chemotherapy was delayed for at least 2 months following the rifampicin-containing regimens. Ethambutol alone did not protect guinea-pigs, nor did it influence the response to isoniazid or to isoniazid plus rifampicin. It was concluded that rifampicin may act selectively on a small proportion of the bacterial population and that it may be unnecessary to prescribe it for long periods in short course chemotherapy in man. Ethambutol does not appear likely to contribute to the sterilizing activity of short course regimens though it may prevent the emergence of drug resistance.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 827836     DOI: 10.1016/s0041-3879(76)80002-5

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  7 in total

1.  Inhaled nitric oxide treatment of patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  Richard Long; Richard Jones; James Talbot; Irvin Mayers; James Barrie; Michael Hoskinson; Bruce Light
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Current concepts in the treatment of tuberculosis.

Authors:  I B Tager
Journal:  West J Med       Date:  1987-04

3.  Resistance to rifampicin and isoniazid in strains of Mycobacterium tuberculosis.

Authors:  S H Siddiqi; A Aziz; Z Reggiardo; G Middlebrook
Journal:  J Clin Pathol       Date:  1981-08       Impact factor: 3.411

4.  Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

Authors:  Zahoor Ahmad; Eric L Nuermberger; Rokeya Tasneen; Michael L Pinn; Kathy N Williams; Charles A Peloquin; Jacques H Grosset; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2010-01-31       Impact factor: 5.790

5.  In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.

Authors:  T Yamamoto; R Amitani; K Suzuki; E Tanaka; T Murayama; F Kuze
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

6.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 7.  Drug treatment for tuberculosis during pregnancy: safety considerations.

Authors:  G Bothamley
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.